S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.63 (-0.04%)
AAPL   171.93 (-0.80%)
MSFT   421.35 (-0.02%)
META   486.71 (-1.45%)
GOOGL   150.95 (+0.05%)
AMZN   180.45 (+0.34%)
TSLA   175.89 (-2.19%)
NVDA   904.46 (+0.22%)
NIO   4.51 (-3.43%)
AMD   180.66 (+0.60%)
BABA   72.37 (+1.09%)
T   17.61 (+0.34%)
F   13.30 (+1.84%)
MU   118.07 (-0.90%)
CGC   8.65 (-9.42%)
GE   175.93 (-2.33%)
DIS   122.53 (+1.28%)
AMC   3.73 (-14.06%)
PFE   27.79 (+0.04%)
PYPL   67.02 (+0.68%)
XOM   116.43 (+1.27%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.63 (-0.04%)
AAPL   171.93 (-0.80%)
MSFT   421.35 (-0.02%)
META   486.71 (-1.45%)
GOOGL   150.95 (+0.05%)
AMZN   180.45 (+0.34%)
TSLA   175.89 (-2.19%)
NVDA   904.46 (+0.22%)
NIO   4.51 (-3.43%)
AMD   180.66 (+0.60%)
BABA   72.37 (+1.09%)
T   17.61 (+0.34%)
F   13.30 (+1.84%)
MU   118.07 (-0.90%)
CGC   8.65 (-9.42%)
GE   175.93 (-2.33%)
DIS   122.53 (+1.28%)
AMC   3.73 (-14.06%)
PFE   27.79 (+0.04%)
PYPL   67.02 (+0.68%)
XOM   116.43 (+1.27%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.63 (-0.04%)
AAPL   171.93 (-0.80%)
MSFT   421.35 (-0.02%)
META   486.71 (-1.45%)
GOOGL   150.95 (+0.05%)
AMZN   180.45 (+0.34%)
TSLA   175.89 (-2.19%)
NVDA   904.46 (+0.22%)
NIO   4.51 (-3.43%)
AMD   180.66 (+0.60%)
BABA   72.37 (+1.09%)
T   17.61 (+0.34%)
F   13.30 (+1.84%)
MU   118.07 (-0.90%)
CGC   8.65 (-9.42%)
GE   175.93 (-2.33%)
DIS   122.53 (+1.28%)
AMC   3.73 (-14.06%)
PFE   27.79 (+0.04%)
PYPL   67.02 (+0.68%)
XOM   116.43 (+1.27%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.63 (-0.04%)
AAPL   171.93 (-0.80%)
MSFT   421.35 (-0.02%)
META   486.71 (-1.45%)
GOOGL   150.95 (+0.05%)
AMZN   180.45 (+0.34%)
TSLA   175.89 (-2.19%)
NVDA   904.46 (+0.22%)
NIO   4.51 (-3.43%)
AMD   180.66 (+0.60%)
BABA   72.37 (+1.09%)
T   17.61 (+0.34%)
F   13.30 (+1.84%)
MU   118.07 (-0.90%)
CGC   8.65 (-9.42%)
GE   175.93 (-2.33%)
DIS   122.53 (+1.28%)
AMC   3.73 (-14.06%)
PFE   27.79 (+0.04%)
PYPL   67.02 (+0.68%)
XOM   116.43 (+1.27%)
NASDAQ:HUMA

Humacyte (HUMA) Stock Price, News & Analysis

$3.11
+0.01 (+0.32%)
(As of 03:59 PM ET)
Today's Range
$3.06
$3.14
50-Day Range
$2.59
$4.84
52-Week Range
$1.96
$5.60
Volume
752,962 shs
Average Volume
936,541 shs
Market Capitalization
$363.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

Humacyte MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
158.1% Upside
$8.00 Price Target
Short Interest
Healthy
4.47% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.54mentions of Humacyte in the last 14 days
Based on 16 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.94) to ($0.64) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.09 out of 5 stars

Medical Sector

372nd out of 938 stocks

Biological Products, Except Diagnostic Industry

52nd out of 154 stocks

HUMA stock logo

About Humacyte Stock (NASDAQ:HUMA)

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

HUMA Stock Price History

HUMA Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Humacyte (NASDAQ:HUMA) Receives Buy Rating from Benchmark
Q4 2023 Humacyte Inc Earnings Call
HUMA Stock Earnings: Humacyte Meets EPS for Q4 2023
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Humacyte GAAP EPS of -$0.24 in-line
What Wall Street expects from Humacyte's earnings
Humacyte (HUMA) Scheduled to Post Quarterly Earnings on Friday
HUMA Apr 2024 5.000 call
Humacyte Shares Rise 10% on Common Stock Offering
BCTX Jul 2024 2.500 put
IMGN Mar 2024 32.000 put(CONTRA
HUMA Mar 2024 5.000 put
IMGN Jul 2024 29.000 call
See More Headlines
Receive HUMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Humacyte and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/22/2024
Today
3/28/2024
Next Earnings (Estimated)
5/10/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:HUMA
Fax
N/A
Employees
164
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.00
High Stock Price Target
$15.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+158.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-110,780,000.00
Pretax Margin
-286,051.62%

Debt

Sales & Book Value

Annual Sales
$1.57 million
Book Value
$1.13 per share

Miscellaneous

Free Float
89,866,000
Market Cap
$361.10 million
Optionable
Optionable
Beta
1.53
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. Laura E. Niklason M.D. (Age 61)
    Ph.D., Founder, President, CEO & Director
    Comp: $717.85k
  • Mr. Dale A. Sander (Age 64)
    CFO, Chief Corporate Development Officer & Treasurer
    Comp: $667.45k
  • Dr. Shamik J. Parikh M.D. (Age 51)
    Chief Medical Officer
    Comp: $514.72k
  • Dr. Juliana L. Blum Ph.D.
    Co-Founder & Executive Advisor
  • Dr. Heather Ledbetter Prichard Ph.D. (Age 46)
    Chief Operating Officer
    Comp: $576.44k
  • Ms. Sabrina Osborne
    Executive Vice President of Business Strategy & People
  • Mr. William John Scheessele (Age 52)
    Chief Commercial Officer
  • Mr. Harold Alterson
    Senior Vice President of Quality
  • Dr. Yang Cao M.D. (Age 58)
    Ph.D., Chief Regulatory Officer

HUMA Stock Analysis - Frequently Asked Questions

Should I buy or sell Humacyte stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Humacyte in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" HUMA shares.
View HUMA analyst ratings
or view top-rated stocks.

What is Humacyte's stock price target for 2024?

4 Wall Street research analysts have issued 12 month price targets for Humacyte's shares. Their HUMA share price targets range from $4.00 to $15.00. On average, they expect the company's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 158.1% from the stock's current price.
View analysts price targets for HUMA
or view top-rated stocks among Wall Street analysts.

How have HUMA shares performed in 2024?

Humacyte's stock was trading at $2.84 at the start of the year. Since then, HUMA shares have increased by 9.2% and is now trading at $3.10.
View the best growth stocks for 2024 here
.

Are investors shorting Humacyte?

Humacyte saw a drop in short interest in the month of March. As of March 15th, there was short interest totaling 3,780,000 shares, a drop of 36.5% from the February 29th total of 5,950,000 shares. Based on an average daily volume of 870,900 shares, the short-interest ratio is currently 4.3 days. Currently, 4.5% of the shares of the stock are short sold.
View Humacyte's Short Interest
.

When is Humacyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our HUMA earnings forecast
.

How were Humacyte's earnings last quarter?

Humacyte, Inc. (NASDAQ:HUMA) announced its quarterly earnings data on Friday, March, 22nd. The company reported ($0.24) earnings per share for the quarter, beating analysts' consensus estimates of ($0.25) by $0.01. During the same period last year, the business posted ($0.21) earnings per share.

What ETFs hold Humacyte's stock?

ETFs with the largest weight of Humacyte (NASDAQ:HUMA) stock in their portfolio include Clough Select Equity ETF (CBSE).Clough Long/Short Equity ETF (CBLS).

Who are Humacyte's major shareholders?

Humacyte's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.02%), Vanguard Group Inc. (3.02%), Northern Trust Corp (0.55%), Charles Schwab Investment Management Inc. (0.47%), GSA Capital Partners LLP (0.42%) and United Asset Strategies Inc. (0.21%). Insiders that own company stock include Brady W Dougan, Dale A Sander, Heather Ledbetter Prichard, Laura E Niklason, Michael T Constantino and William John Scheessele.
View institutional ownership trends
.

How do I buy shares of Humacyte?

Shares of HUMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:HUMA) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners